DrugPatentWatch Database Preview
Details for Patent: 7,803,839
Which drugs does patent 7,803,839 protect, and when does it expire?
Patent 7,803,839 protects COTELLIC and is included in one NDA.
This patent has forty-five patent family members in thirty countries.
This patent has forty-five patent family members in thirty countries.
Summary for Patent: 7,803,839
| Title: | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| Abstract: | Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. |
| Inventor(s): | Aay; Naing (San Mateo, CA), Anand; Neel Kumar (Burlingame, CA), Blazey; Charles M. (San Francisco, CA), Bowles; Owen Joseph (Pacifica, CA), Bussenius; Joerg (Foster City, CA), Costanzo; Simona (Los Altos, CA), Curtis; Jeffry Kimo (San Anselmo, CA), DeFina; Steven Charles (Burlingame, CA), Dubenko; Larisa (San Francisco, CA), Joshi; Anagha Abhijit (Fremont, CA), Kennedy; Abigail R. (Oakland, CA), Kim; Angie Inyoung (San Mateo, CA), Koltun; Elena S. (Foster City, CA), Manalo; Jean-Claire Limun (Daly City, CA), Peto; Csaba J. (Alameda, CA), Rice; Kenneth D. (San Rafael, CA), Tsang; Tsze H. (El Cerrito, CA) |
| Assignee: | Exelixis, Inc. (South San Francisco, CA) |
| Application Number: | 11/995,928 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 7,803,839
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 7,803,839
| PCT Information | |||
| PCT Filed | October 05, 2006 | PCT Application Number: | PCT/US2006/039126 |
| PCT Publication Date: | April 19, 2007 | PCT Publication Number: | WO2007/044515 |
Non-Orange Book US Patents Family Members for Patent 7,803,839
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,362,002 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | ➤ Sign Up |
| 2,017,166,523 | ➤ Sign Up | |
| 7,915,250 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 7,803,839
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 504565 | ➤ Sign Up | |||
| Australia | 2006302415 | ➤ Sign Up | |||
| Brazil | PI0617165 | ➤ Sign Up | |||
| Canada | 2622755 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
